Biogen wins patent challenge to key multiple sclerosis drug - STAT

Biogen wins patent challenge to key multiple sclerosis drug - STAT

Biogen wins patent challenge to key multiple sclerosis drug

By ADAM FEUERSTEIN

RUBY WALLAU FOR STAT

Mylan had filed an inter partes review seeking to overturn the last remaining patent on Tecfidera, Biogen’s most important multiple sclerosis drug.

READ MORE